Salarius Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Decoy Therapeutics

13/05/2024 23:02

* Salarius Pharmaceuticals Inc  SLRX.OQ  reported a
quarterly
adjusted loss of 41 cents​​ per share for the quarter ended in
March, higher than the same quarter last year, when the company
reported EPS of $-2.23.  The lone analyst forecast for the
quarter was for a loss of $6.70 per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * Salarius Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of 41 cents​.
    * Salarius Pharmaceuticals Inc shares had fallen by 5.4%
this
quarter and lost 23.1% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 737.5% in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * 
    * Wall Street's median 12-month price target for Salarius
Pharmaceuticals Inc is $3.25 

This summary was machine generated from LSEG data May 13 at
10:02 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -6.70          -0.41          Beat
                                  -0.22          
 Sep. 30 2023      -1.20          -0.65          Beat
 Jun. 30 2023      -1.30          -1.43          Missed